Galenica confirms earnings guidance for 2018 despite weaker sales growth

As Galenica previously announced on the release of its 2018 half-year results, the additional and higher than originally announced price reduction measures for medications by the authorities are impacting on sales growth. Galenica therefore expects sales growth for 2018 to be below the 2% forecast. However, management of the Galenica Group is confident of achieving the announced EBIT growth. Consequently, the outlook regarding proposal of a dividend of at least at the same level as the prior year to the Annual General Meeting in 2019 is unchanged.